MétaCan
Menu
← Back to cohort

Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Patient-reported outcomes (PROs) from CREST.

2025· article· en· W4410816943 on OpenAlexaff
Jens Bedke, Neal D. Shore, Thomas Powles, Matthew D. Galsky, Joan Palou, Daniel R. Saltzstein, Félix Guerrero‐Ramos, Motonobu Nakamura, Tilman Todenhöfer, Raj Satkunasivam, Peter Black, Julia Brinkmann, Jane P. Chang, Anthony Eccleston, Arlene Reisman, Jennifer Vermette, Gary D. Steinberg

Bibliographic record

VenueJournal of Clinical Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsMedicineBladder cancerUrothelial cancerCancerBacillus (shape)Internal medicineOncologyGynecology

Abstract

fetched live from OpenAlex

4610 Background: Sasanlimab with BCG (induction [IND] + maintenance [MNT]) significantly improved investigator-assessed EFS vs BCG (IND + MNT) and had a manageable safety profile in patients (pts) with BCG-naive, high-risk NMIBC in the phase 3 CREST study primary analysis. We report PRO data not previously presented from CREST for Arms A and C assessing the impact of sasanlimab with BCG on QOL. Methods: Eligible pts were randomized 1:1:1 to receive sasanlimab with BCG (IND + MNT; Arm A), sasanlimab with BCG (IND; Arm B), or BCG (IND + MNT; Arm C). PROs were secondary endpoints and not included in the testing hierarchy. PROs were assessed prior to first dose (baseline [BL]), and at scheduled visits until an event or end of treatment (every 4 wk until Wk 28, every 12 wk until Wk 100) and at disease follow-up using the EORTC QLQ-C30 and QLQ-NMIBC24. Longitudinal mixed effect-model analyses were used to assess change from BL in the EORTC QLQ-C30 and NMIBC24 items. Results: At data cutoff (Dec 2, 2024), 695/703 pts randomized to Arms A (n = 348) and C (n = 347) had a BL score and ≥1 post-BL score. Completion rates were > 84% for all visits through the end-of-treatment visit (Cycle 25). QLQ-C30 Global Health Score QOL scores were numerically similar between arms (mean difference: −2.345; 95% CI: −4.058, −0.632; P = 0.007). No clinically meaningful differences (≥10-point change; Osoba et al. JCO 1998) were observed across urinary symptoms (NMIBC24; mean difference: 0.851; 95% CI: −1.030 , 2.731; P = 0.375), intravesical treatment issues (NMIBC24; mean difference: 1.271; 95% CI: −0.587, 3.130; P = 0.180), and EORTC QLQ-C30 items (Table) between arms, except in a small sample for female sexual problems (NMIBC24; mean difference: 18.502; 95% CI: 6.228, 30.775; P = 0.007). Results were statistically significant but not clinically meaningful. Conclusions: PROs from CREST showed QOL was maintained when combining sasanlimab with BCG vs BCG (both IND + MNT). These results can help inform the benefit-risk assessment of CREST. Clinical trial information: NCT04165317 . Arm AEstimated mean (95% CI)n=348 Arm CEstimated mean (95% CI)n=347 Estimated mean difference (95% CI) P value Physical functioning −2.485(−3.493, −1.477) −0.261(−1.272, 0.750) −2.224(−3.651, −0.796) 0.002 Role functioning −4.836(−6.187, −3.484) -0.910(−2.265, 0.445) −3.926(−5.840, −2.012) 0.000 Emotional functioning 0.074(−1.046, 1.194) 2.071(0.948, 3.194) −1.997(−3.583, −0.411) 0.014 Cognitive functioning −2.137(−3.174, −1.101) −0.832(−1.872, 0.208) −1.305(−2.774, 0.163) 0.081 Social functioning −3.863(−5.111, −2.615) −0.415(−1.666, 0.836) −3.448(−5.215, −1.681) 0.000 Fatigue 4.881(3.488, 6.274) 1.211(−0.185, 2.607) 3.670(1.698, 5.642) 0.000 Nausea and vomiting 0.908(0.473, 1.343) 0.545(0.108, 0.982) 0.363(−0.253, 0.980) 0.248 Pain 2.784(1.519, 4.048) −0.174(−1.443, 1.095) 2.958(1.166, 4.749) 0.001

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.045
GPT teacher head0.401
Teacher spread0.356 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicBladder and Urothelial Cancer Treatments→French-language works237,207→